Sean E. Aeder

Array ( [id] => 17329232 [patent_doc_number] => 11219673 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-11 [patent_title] => Compositions and methods for delivery of biomacromolecule agents [patent_app_type] => utility [patent_app_number] => 15/561374 [patent_app_country] => US [patent_app_date] => 2016-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 39 [patent_no_of_words] => 38146 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15561374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19014191 [patent_doc_number] => 11921115 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-05 [patent_title] => Prostate antigen standards and uses thereof [patent_app_type] => utility [patent_app_number] => 15/081331 [patent_app_country] => US [patent_app_date] => 2016-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 9358 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 199 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15081331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19014191 [patent_doc_number] => 11921115 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-05 [patent_title] => Prostate antigen standards and uses thereof [patent_app_type] => utility [patent_app_number] => 15/081331 [patent_app_country] => US [patent_app_date] => 2016-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 9358 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 199 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15081331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11074267 [patent_doc_number] => 20160271231 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-22 [patent_title] => 'TREATING CANCER STEM CELLS USING TARGETED CARGO PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/080038 [patent_app_country] => US [patent_app_date] => 2016-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 25611 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15080038 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12627087 [patent_doc_number] => 20180100859 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-12 [patent_title] => SURROGATE FUNCTIONAL BIOMARKER FOR SOLID TUMOR CANCER [patent_app_type] => utility [patent_app_number] => 15/560636 [patent_app_country] => US [patent_app_date] => 2016-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15560636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11061971 [patent_doc_number] => 20160258933 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-08 [patent_title] => 'METHODS OF DETERMINING CELLULAR CHEMOSENSITIVITY' [patent_app_type] => utility [patent_app_number] => 15/073391 [patent_app_country] => US [patent_app_date] => 2016-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 17291 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15073391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16197387 [patent_doc_number] => 10722523 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-28 [patent_title] => Chemoimmunotherapy for epithelial cancer [patent_app_type] => utility [patent_app_number] => 15/558439 [patent_app_country] => US [patent_app_date] => 2016-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 17636 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15558439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11061971 [patent_doc_number] => 20160258933 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-08 [patent_title] => 'METHODS OF DETERMINING CELLULAR CHEMOSENSITIVITY' [patent_app_type] => utility [patent_app_number] => 15/073391 [patent_app_country] => US [patent_app_date] => 2016-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 17291 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15073391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12637206 [patent_doc_number] => 20180104232 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => METHODS FOR DETERMINING PROGNOSIS FOR BREAST CANCER PATIENTS [patent_app_type] => utility [patent_app_number] => 15/556474 [patent_app_country] => US [patent_app_date] => 2016-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28091 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15556474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11048860 [patent_doc_number] => 20160245817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-25 [patent_title] => 'MUCIN 5B AS A PANCREATIC CYST FLUID SPECIFIC BIOMARKER FOR ACCURATE DIAGNOSIS OF MUCINOUS CYSTS AND OTHER MARKERS USEFUL FOR DETECTION OF PANCREATIC MALIGNANCY' [patent_app_type] => utility [patent_app_number] => 15/066273 [patent_app_country] => US [patent_app_date] => 2016-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 26374 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15066273 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12178722 [patent_doc_number] => 20180037657 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO FLT3 PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/556587 [patent_app_country] => US [patent_app_date] => 2016-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 54196 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15556587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14031345 [patent_doc_number] => 10227411 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-03-12 [patent_title] => Modulation of T cells with bispecific antibodies and FC fusions [patent_app_type] => utility [patent_app_number] => 15/063441 [patent_app_country] => US [patent_app_date] => 2016-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 251 [patent_figures_cnt] => 269 [patent_no_of_words] => 41752 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15063441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14485181 [patent_doc_number] => 10329358 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-25 [patent_title] => Anti-human membrane-type ADAM28 antibody [patent_app_type] => utility [patent_app_number] => 15/556177 [patent_app_country] => US [patent_app_date] => 2016-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 10676 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15556177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16697901 [patent_doc_number] => 10948492 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers [patent_app_type] => utility [patent_app_number] => 15/553225 [patent_app_country] => US [patent_app_date] => 2016-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 6 [patent_no_of_words] => 55125 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15553225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10981688 [patent_doc_number] => 20160178632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-23 [patent_title] => 'USE OF MARKERS IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER' [patent_app_type] => utility [patent_app_number] => 15/059238 [patent_app_country] => US [patent_app_date] => 2016-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 45695 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15059238 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12405243 [patent_doc_number] => 09968676 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-15 [patent_title] => Subcutaneous anti-HER2 antibody formulations and uses thereof [patent_app_type] => utility [patent_app_number] => 15/053217 [patent_app_country] => US [patent_app_date] => 2016-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 22328 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15053217 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10823730 [patent_doc_number] => 20160169895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-16 [patent_title] => 'FLAP ENDONUCLEASE-1 AS A MARKER FOR CANCER' [patent_app_type] => utility [patent_app_number] => 15/046525 [patent_app_country] => US [patent_app_date] => 2016-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 15403 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15046525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16381976 [patent_doc_number] => 10806787 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-20 [patent_title] => Anticancer agents or antimetastatic agents using FSTL1 and combination drug thereof [patent_app_type] => utility [patent_app_number] => 15/550461 [patent_app_country] => US [patent_app_date] => 2016-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 151 [patent_figures_cnt] => 155 [patent_no_of_words] => 246438 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 304 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15550461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11395538 [patent_doc_number] => 20170016073 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'NOVEL ESTROGEN RECEPTOR MUTATIONS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/018640 [patent_app_country] => US [patent_app_date] => 2016-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 50396 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15018640 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11092798 [patent_doc_number] => 20160289766 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-06 [patent_title] => 'MOLECULAR PROGNOSTIC SIGNATURE FOR PREDICTING BREAST CANCER METASTASIS, AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/014294 [patent_app_country] => US [patent_app_date] => 2016-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 28079 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15014294 [rel_patent_id] =>[rel_patent_doc_number] =>)